Objective: The objective of this study was to examine cognitive and quality-of-life measures/quality of life outcomes with adjunctive lacosamide therapy in patients with treatment-resistant partial epilepsy. Methods: This was a prospective, open-label, nonblinded, adjunctive therapy test-retest (within subjects) study of patients with treatment-resistant partial epilepsy in which outcome (cognitive functioning and mood/quality of life) was measured in the same subject before and after adjunctive lacosamide administration for 24 weeks. Lacosamide was started at 100 mg (50 mg twice daily) and could be titrated as needed up to 400 mg/day (200 mg twice daily). Baseline concomitant AEDs were kept constant. Composite scores were calculated for a pre-post difference score for the cognitive and mood/quality-of-life measures separately and used in regression analyses to correct for the effects of age, education, seizure frequency, seizure severity, dose of lacosamide, and number of AEDs at baseline. Results: Thirty-four patients were enrolled (13 males, 21 females). Mean age was 38.8 ± 2.43 years. Mean seizure frequency decreased significantly from 2.0 ± 2.55 seizures per week at baseline to 1.02 ± 1.72 seizures per week at posttreatment (t = 4.59, p b .0001) with a 50% responder rate seen in 18 patients (52.9%). No significant differences were found on the composite scores of the cognitive or the mood/quality-of-life measures after 6 months of lacosamide. Significance: Lacosamide appeared to have low risks of significant changes in cognition or mood/quality of life. In addition, the present study supports prior studies that have proven lacosamide as an effective adjunctive therapy for the treatment of resistant partial epilepsy.
Introduction
Lacosamide is a third-generation antiepileptic drug available in multiple formulations which was approved as adjunct treatment for partialonset epilepsy in adults by the US Food and Drug Administration (FDA) in 2008 and as monotherapy in 2014. Three randomized, controlled trials (RCTs) of lacosamide as adjunct treatment for medically intractable epilepsy [1] [2] [3] and three long-term follow-up studies [4] [5] [6] revealed a significant anticonvulsant effect. Lacosamide has also demonstrated a good safety profile with a small degree of adverse events. The most common adverse events reported were diplopia, dizziness, nausea, and headaches [1] [2] [3] [4] [5] [6] .
Limited data exist regarding the effect of lacosamide on mood and cognition. In the pooled analysis of adverse effects (AEs) from the 3 RCTs [1] [2] [3] , self-reported rates of "memory impairment" were seen in 2% of the composite treatment arm vs. 1% in the placebo arm, and depression was noted in 2% in the composite treatment arm vs. 1% in the placebo arm. Lacosamide, like all other AEDs, has a warning for suicidality though there are no specific data to suggest an increased risk. Other data regarding mood/cognition have been limited to small prospective uncontrolled or retrospective studies. IJff et al. [7] studied patients with refractory partial-onset epilepsy prospectively before and after lacosamide was added as adjunctive therapy. The authors reported that patients had increased subjective complaints but that, objectively, they did not do worse with lacosamide on a computerized task [7] . Helmstaedter and Witt retrospectively studied the impact of adjunctive lacosamide and compared it with that of topiramate and lamotrigine in a naturalistic outpatient setting and concluded that cognitive effects were equivalent to lamotrigine and better than topiramate [8] . As for mood, the effects of lacosamide on depression and anxiety were retrospectively studied in patients with partial-onset epilepsy by Moseley et al. [9] . The authors concluded that lacosamide did not worsen depression or anxiety. Giorgi et al. [10] conducted a small study assessing depression and anxiety on 10 patients and found no changes after the use of lacosamide.
Understanding the cognitive and behavioral side effect profile of AEDs is important to clinical practice since changes in these areas could affect quality of life and adherence with the medication. This study is the first prospective comprehensive study of cognitive and mood/quality-of-life side effects of lacosamide on patients with refractory partial epilepsy using a neuropsychological battery of tests for assessment of attention, concentration, psychomotor speed, verbal and nonverbal learning and verbal fluency, as well as mood/quality-of-life measures and evaluation of adverse/side effects. In contrast to the other two prospective studies, we used a testing battery that was inclusive and sensitive to a range of cognitive functions.
Our study had two objectives: to investigate whether lacosamide affects cognition and mood/quality of life and to determine if any significant changes in cognition or mood/quality of life were dependent on covariates including age, sex, education, number of AEDs, seizure frequency and seizure severity at baseline, and final drug dose at the end of the trial.
Methods

Patient population and study design
This was a prospective, open-label, nonblinded, adjunctive therapy test-retest (within subjects) study of patients with uncontrolled partial epilepsy in which outcome (cognitive functioning and mood/ quality of life) was measured in the same subject before and after adjunctive lacosamide administration. This design was chosen since it best emulates what occurs in clinical practice. All procedures were done with prior approval from the Copernicus Group IRB (CGIRB; Durham, NC) #: MLA1-10-124.
The inclusion criteria were as follows: (1) ages 18-70 years; (2) able and willing to provide written informed consent in accordance with the International Conference on Harmonisation (ICH) and Good Clinical Practice (GCP) guidelines; (3) a native English speaker or balanced bilingual; (4) diagnosis of refractory partial-onset epilepsy; and (5) historical mean seizure frequency of at least 2 seizures per month for the 6 months prior to the first visit.
The exclusion criteria were as follows: (1) subjects with a history of drug or alcohol abuse; (2) pregnant females or those using an unreliable method of contraception; (3) diagnosis of a major psychiatric disorder (bipolar disorder, schizophrenia, psychotic disorder, major depression) requiring hospitalization in the past 2 years or the presence of other psychological or behavioral conditions that the investigator judged should grounds for exclusion from the study; (4) currently using an antidepressant, anxiolytic, or antipsychotic agent; (5) active suicidal plan or suicidal thoughts in the past 6 months; (6) presence of a progressive, demyelinating, or degenerative neurological condition; (7) diagnosis of psychogenic nonepileptic seizure disorder; (8) a history of traumatic brain injury or of cardiac arrhythmia; and (9) impaired intelligence quotient (estimated Full Scale IQ b 70).
Withdrawal criteria included the following: (1) subjects who endorsed suicidality, (2) any episode of status epilepticus, (3) need for use of rescue benzodiazepine more than once per week, (4) any laboratory abnormalities which were deemed by the investigator to be clinically significant, (5) any clinically significant objective clinical signs or symptoms that were intolerable or incapacitating to the patient and/or pose a serious threat to well-being, (6) nonadherence with study protocol (b 80% compliance with study medication), (7) females who became pregnant during the study, (8) 
Study visits
The study was spread over 28 weeks and was divided into three phases: screening (visit 0), titration/treatment phase (visits 1, 2, 3), and termination phase (visit 4) (Fig. 1) . Screening duration was 4 weeks, visit 1 was at 4 weeks after screening, visit 2 at 6 weeks, visit 3 at 18 weeks, and visit 4 (termination phase) at 28 weeks. Telephone calls were made 2 weeks after screening and at weeks 6, 10, 14, 22, and 26 to obtain seizure frequency and seizure severity data to assess compliance with the daily diary and to monitor adverse events and changes in concomitant medications.
At the screening visit (visit 0), eligibility assessment was performed, and written informed consent was obtained. Baseline demographic data included seizure history, type and frequency, AED use history, medical history, and psychiatric history collected. Measurement of vital signs, body weight, and height and physical and neurological examination were performed. Laboratory safety studies (urinalysis, hematology, chemistries, and serum or urine pregnancy tests as appropriate) and urine pregnancy tests were obtained. Subjects were trained in maintenance of a seizure diary to be kept throughout the study. After the screening visit, laboratory testing was done only if clinically indicated.
Over a 4-week baseline period, subjects were assessed on compliance with the daily diary, and screening test results were reviewed with a telephone call from the study coordinator at week 2. All concomitant AEDs were kept stable during the 4-week baseline period.
During visit 1 (week 4), inclusion and exclusion criteria and seizure diaries were reviewed. If the subject still met the eligibility criteria, the drug was dispensed as described below (Section 2.3). During all visits after the screening visit (visits 1, 2, 3, 4), physical and neurological examinations were performed, and vital signs, seizure frequency, seizure severity, and adverse events data were collected.
After completion of the study, subjects were given an option to taper off the drug after visit 4 (i.e., after a minimum of 28 weeks into the study). In this study, 3 out of the 34 subjects elected to taper off medication. Subjects who wished to remain on the drug continued to receive it as a prescription medication. A summary of the protocol can be seen in Table 1 
Drug dosing
Lacosamide was provided by UCB (Brussels, Belgium) in the form of capsules containing 50 mg, 100 mg, 150 mg, and 200 mg. Lacosamide was dispensed at 50 mg bid (100 mg total daily dose) at visit 1. Drug adherence was calculated at all visits. All concomitant medications for epilepsy were kept stable throughout the study.
The dose of lacosamide was adjusted throughout the course of the study by the investigator depending on the seizure frequency and severity and adverse event profile of the subject. The standard study drug-dosing schedule was as follows: lacosamide was titrated starting from visit 1 for 2 weeks (50 mg bid) up to a therapeutic dosage as determined by the investigator with a maximum of 400 mg/day.
Analysis of seizures
Subjects were interviewed at baseline to characterize their seizure types and then assigned a code to enter into the seizure diary. Diaries were reviewed at each visit by the study coordinator and PI to determine seizure frequency. The predrug baseline seizure frequency was calculated over 28 days prior to visit 1. The two-week-long initial titration period after visit 1 was not taken into account for the final frequency count. The postdrug seizure count was taken as the raw number of seizures which was over the remaining 22 weeks of drug treatment.
Severity of seizures was assessed through the use of the Liverpool Seizure Severity Scale 219 [11] . This scale has 12 questions which provide a single score for seizure severity. The Liverpool Seizure Severity Scale was given at baseline and at the end of the study (visit 4) at 28 weeks.
Adverse event monitoring
An adverse event was defined as any untoward medical occurrence without necessarily a causal relationship with the treatment (i.e., lacosamide). This could include clinically significant symptoms and signs, changes in physical examination findings, abnormal laboratory test findings, hypersensitivity, and worsening of epilepsy. Adverse events were assessed in three different ways: 1) by documenting all adverse reactions as well as their intensity (mild, moderate, or severe) throughout the study and whether any action was taken, 2) by using an adverse event profile, and 3) with the A-B neurotoxicity profiles. The adverse event profile captures nineteen types of adverse events [12] [13] [14] rated on a 4-point Likert scale with 1, never a problem; 2, rarely a problem; 3, sometimes a problem; and 4, always a problem. The A-B neurotoxicity profiles [15] capture central nervous system side effects through 33 questions that reflect how the individual perceives his/her cognitive/behavioral functioning. Higher scores represent greater cognitive interference.
Neuropsychological testing
The neuropsychological test battery was derived using several guiding principles. Whenever possible, tasks from previous research on AEDs by American investigators, which are sensitive to AED effects, were administered in a standardized manner and were sensitive to the measurement of specific cognitive functions were selected. Consequently, even though the current study was not performing a direct drug to drug comparison, inferences could be made from the effects of lacosamide to other AEDs with similar study protocols. Additionally, tests were chosen based on short length and relatively low difficulty levels in order to reduce subject dropout.
Neuropsychological testing was divided into cognitive and mood/ quality-of-life measures and was done at visits 1 and 4 to analyze changes from pre to posttreatment. The cognitive tests were selected to assess specific domains. The Wechsler Test of Adult Reading provided a premorbid intellectual quotient estimate at the first test session. Memory was assessed with the Buschke Selective Reminding Test [16] and the Brief Visuospatial Memory Test-Revised [17, 18] . The Wechsler Adult Intelligence Scale-III Digit Span test [19] assessed attention. Cognitive speed and inhibition were measured with the Stroop Color Word Test [16] , psychomotor speed and alternation of cognitive set was assessed with the Trail Making Test [16] , visuomotor speed was tested with the Symbol Digit Modalities Test [16] , and timed verbal and semantic fluency were tested with the Controlled Oral Word Association Test and a categorical fluency measure [16] . The second test administration used parallel forms for the following measures: Controlled Oral Word Association Test, Buschke Selective Reminding Test, Brief Visuospatial Memory Test, Symbol Digit Modalities Test, and Digit Cancellation Test. Mood/quality-of-life assessment included the following: the Beck Depression Inventory -Second Edition to assess depressive symptoms [20] , the Profile of Mood States (POMS) [21] for multiple mood states, and the Quality of Life in Epilepsy Inventory-89 for quality of life (QOLIE-89) [22] . Selected scales from the QOLIE-89 that are the most sensitive to epilepsy and AED effects were examined to reduce the number of variables (attention, language, memory, and overall).
The question of practice effects when conducting test-retest trials is an important factor in neuropsychology. Fortunately, "except for single solution tests and others with a significant learning component, large changes between test and retest are not common" [23] .
Whenever possible, our study employed tests that have an alternate form (Form A administered in Trial 1 and Form B administered in Trial 
Data analysis
The SPSS 22.0 software was used to assess cognitive functioning and mood/quality of life in those taking lacosamide which was the primary endpoint. In order to reduce the number of variables, a mean standardized difference score was calculated separately for the mood/quality of life and cognitive measures to produce a behavioral composite and a cognitive composite. A difference score was calculated between the predrug and postdrug evaluations for each of the variables ( Table 2) . The difference score for each measure was then standardized (Z score), and the mean difference score across measures was calculated. This method produced one cognitive composite and one mood/quality-of-life composite representing change over the duration of the drug trial. These composites were individually subjected to a KolmogorovSmirnov test to determine fit to a normal distribution in order to determine if the use of a one-sample t-test would be valid. Statistical significance for the two-sided one-sample t-test was set at p b 0.05.
The secondary objective was to determine whether changes in cognition or mood were dependent upon the predictors of age, sex, education, number of AEDs at screening, seizure severity and seizure frequency after the baseline, and final drug dose at visit 4. For this analysis, a full linear model with stepwise regression was run separately for the mood composite and the cognitive composite as dependent variables and the six predictor variables as covariates. If the residuals from the regressions were normally distributed, the p-values of the t-tests in the backward stepwise selection procedure were deemed accurate. The optimal model was determined to be significant if the intercept from the regression was significant at p b 0.05.
In order to also determine individual differences, significance was established as ± 2 SD from the group mean for cognitive and mood composite scores.
To understand the effects of lacosamide on different domains, paired sample t-tests were performed on the predrug and postdrug cognitive and mood variables, with a Bonferroni correction applied within each to determine statistical significance (p b 0.003 for the cognitive measures and p b 0.004 for the mood measures).
Another analysis was made of seizure frequency, seizure severity, neurotoxicity, and adverse profile scales before and after treatment with a one-sample paired t-test. Statistical significance for this twosided t-test was set at p b 0.05. The effect size (Cohen's d) was calculated for each of the change scores for the cognitive and mood variables.
Results
Demographics
A total of 36 subjects were enrolled and started on lacosamide. One discontinued because of relocation, and one patient was disqualified because data from one trial were corrupted and lost. Thus, a total of 34 subjects (13 males and 21 females) completed the study. The average age was 38.8 ± 2.43 years, and average education was 13.2 ± 0.34 years. Sixteen patients were Caucasians, 10 were African-American, and 8 were Hispanic. Mean dose of lacosamide at visit 4 was 235 mg/day. The average number of concomitant AEDs that subjects were taking at the time of screening was 2.0 ± 0.14. Nine subjects were on 1 AED, 16 subjects were taking 2 AEDs, 7 subjects were on 3 AEDs, and 2 subjects were on 4 AEDs. Twenty patients had temporal lobe epilepsy (10 left, 5 right, and 5 bilateral), 6 had frontal lobe epilepsy (1 left, 2 right, 2 bilateral, 1 undetermined), and 8 had partial epilepsy without further localization (3 right, 1 left, 3 undetermined, 1 bilateral). Details for each patient can be seen in Table 3 . Table 2 Table showing data for various cognitive variables -the tasks administered and the number of subjects for the particular task (n) are shown. Mean and standard error (SE) before lacosamide administration ('Pre'), after lacosamide ('Post') and difference ('Diff') are shown, as well as 't' and 'p' values. 
Reported adverse events
Self-reported AEs included mild headaches in 10 patients, dizziness in 7, mild tiredness in 7, gastrointestinal symptoms (constipation/ diarrhea) in 7, memory/attention concerns in 4, irritability in 3, depressive symptoms in 3, slurred speech in 1, and thirst in 1. The adverse event profile showed a baseline average score of 23.82 ± 1.77 at baseline vs. 20.82 ± 1.90 after lacosamide (n = 34, t = 1.88, p = 0.06). The neurotoxicity scale revealed a mean baseline score of 10.79 ± 1.21 vs. 10.68 ± 1.16 after lacosamide (n = 34, t = 0.9, p = 0.92).
Efficacy/effectiveness
Mean seizure frequency decreased significantly from 2.0 ± 2.55 seizures per week at baseline to 1.02 ± 1.72 seizures per week at posttreatment (t = 4.59, p b 0.0001) with a 50% responder rate seen in 18 patients (52.9%), seizure freedom in 3 (8.8%), and increase in frequency in 4 (11.8%). There was no significant difference for the Liverpool Seizure Severity Scale, with a pretreatment mean score of 47.82 ± 3.79 vs. 46.57 ± 3.65 posttreatment (n = 34, t = 0.74, p = 0.46).
Cognitive outcomes
The Kolmogorov-Smirnov test showed the cognitive composite to be normally distributed (Z = 0.401, p = 0.997). The two-sided one-sample t-test was not statistically significant (t = − 0.343, p = 0.734), indicating no change in overall cognitive scores over the duration of the drug trial, assuming no adjustment for the effects of the covariate predictors. In the full linear model, the residual was normally distributed (Kolmogorov-Smirnov Z = 0.546, p = 0.927). The optimal model from the regression (F = 9.43, p = 0.005) retained the intercept and seizure frequency at the end of the drug trial (t = − 3.07, p = 0.005). This regression indicates that there was no significant change in overall cognitive scores over the duration of the drug trial after adjusting for the linear effects of the covariates except for final seizure frequency, which was significantly related to the cognitive composite score. Individual test score comparisons can be seen in Table 2 . No single score reached statistical significance. When individual patients were considered, only 3 had significant changes with two patients exhibiting significant improvement and one exhibiting a significant worsening in the composite (Table 4) .
Mood/quality-of-life outcomes
The Kolmogorov-Smirnov test showed the mood/quality-of-life composite to be normally distributed (Z = 0.716, p = 0.685). The two-sided one-sample t-test was not significant (t = 0.191, p = 0.85), indicating no change in mood/quality of life over the duration of the drug trial, assuming no adjustment for the effects of the covariate predictors. In the full linear model, the residual was normally distributed (Z = 0.775, p = 0.585). The optimal model from the regression retained only the intercept. No covariates were statistically significant. There was thus no change in overall mood/quality of life over the duration of the study after adjusting for the linear effects of the covariates. Individual test score comparisons can be seen in Table 3 . No single score reached statistical significance. When individual patients were considered, only 1 exhibited a significant change which was an improvement in the composite (Table 4 ).
Discussion
To our knowledge, this study is the first prospective examination of the effects of lacosamide on cognition and mood with a comprehensive neuropsychological battery in an adjunctive trial with patients with epilepsy. Findings from the present study support the assertion that lacosamide has low risks of adverse mood effects. There also appear to be low risks of an overall effect on cognition, although a multiple regression analysis showed an effect of seizure frequency on cognition. There was also a significant reduction in seizure frequency after the 24-week trial of lacosamide which is supportive of prior studies that have shown that lacosamide is effective as an adjunct therapy in refractory partial epilepsy.
Our study examined cognition with a comprehensive prospective analysis of attention, concentration, psychomotor speed, verbal and nonverbal learning, and fluency and found that the addition of lacosamide to the patient's baseline regimen did not result in significant changes in overall cognitive functions. Our results are consistent with previous studies. IJff et al. [7] examined 33 patients with refractory partial epilepsy in which lacosamide was added to their previous AED regimen. Two psychometric tools were used: the SIDAED and the Computerized Visual Searching Task (CVST). The SIDAED is a scale that assesses 46 subjective complaints including general CNS irritability, depressive symptoms, cognitive function, motor problems, visual complaints, headache, cosmetic and dermatologic complaints, gastrointestinal complaints, and sexuality and menses. The CVST assesses reaction time on changing screens. The authors found that the CVST showed significantly faster information-processing reaction times at the second evaluation. Surprisingly, the self-reported SIDAED showed an increase in complaints about cognitive function after the addition of lacosamide. The authors offered the phenomenon of "doing better, feeling worse" as a potential explanation. However, because the cognitive assessment in this study was limited to reaction times while the SIDAED assesses for several other cognitive functions including memory, speech, and concentration, it is not possible to know whether these subjective/objective divergences are due to limited objective measures. In contrast with IJff's findings, our patients did not report adverse effects or self-reported cognitive problems. Our study differs from IJff's study in that we used a comprehensive set of neuropsychological tests that are sensitive measures of attention, concentration, verbal and nonverbal learning, Table 3 Table showing data for various mood/quality-of-life variables -the tasks administered and the number of subjects for the particular task (n) are shown. Mean and standard error (SE) before lacosamide administration ('Pre'), after lacosamide ('Post') and difference ('Diff') are shown, as well as 't' and 'p' values. verbal fluency, and psychomotor speed. The other principal difference between the two studies is that we had a fixed protocol while IJff's study was done in a "naturalistic setting". As a result, times for testing varied from patient to patient. Helmstaedter and Witt [8] compared cognitive functions in those receiving lacosamide (n = 44) with topiramate (n = 15) and lamotrigine (n = 11) in a retrospective study in a naturalistic outpatient setting. Patients were studied at baseline and after a median follow-up interval of 32 weeks with the Epitrack for executive function (response-inhibition, visuomotor speed, mental flexibility, visual motor planning, verbal fluency, and working memory), a German adaptation of the Rey Auditory Verbal Learning Test, a subjective rating of self-perceived side effects (cognition, behavior, and physical/physiological symptoms), and the QOLIE-10 for quality of life. The authors concluded that objective and subjective measures demonstrated that the cognitive side effect profile of lacosamide is comparable with that of lamotrigine and superior to topiramate. The main limitations of this study were the small number of subjects in each subgroup and its retrospective nature. With regard to depression, mood, and quality of life, our findings are consistent with previous reports; lacosamide does not appear to have negative side effects on mood/quality of life. Moseley et al. [9] examined the potential effects of lacosamide on depression and anxiety in a retrospective study of 91 patients with partial-onset epilepsy using the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) and the Generalized Anxiety Disorder-7-item scale (GAD-7). It was concluded that lacosamide did not have a negative effect on depression or anxiety. This study's main limitations are that it was a retrospective chart review, not controlled and limited to the study of depression and anxiety without assessing for other cognitive or behavioral domains. Giorgi et al. [10] conducted a small prospective open study on 10 patients with partial epilepsy, comparing depression scores utilizing the BDI and anxiety scores with the State Trait Anxiety Inventory (STAI) before and after the administration of lacosamide. They found no significant changes. The primary limitation of this study was that it had a very small sample and was limited to the assessment of depression and anxiety only. While no significant changes were determined on the composite score that combined depression (BDI-II), mood (POMS), and quality of life (QOLIE-89), individual depression scores, the BDI and POMS depression, and vigor scores showed a trend towards improvement after treatment with lacosamide. Along similar lines, Moseley et al. [9] reported that lacosamide demonstrated a positive effect on a specific subgroup of patients who initially presented with elevated NDDI-E scores suggestive of major depressive disorder. Lacosamide's mechanism of action enhances slow inactivation of sodium channels [28] , and as such, it might share the 'mood stabilizing' effect with other AEDs, including carbamazepine, oxcarbazepine, valproate, and lamotrigine, all which enhance the fast inactivation of sodium channels. Whether lacosamide has an antidepressant effect will need to be further investigated.
In the current study, lacosamide was well-tolerated and efficacious with a significant decrease in seizure frequency and 50% responder rates which are comparable with those in larger studies [1] [2] [3] [4] [5] [6] . The most commonly reported AEs were mild headaches, dizziness, mild tiredness, and gastrointestinal symptoms. These findings coincide with most of the reported series [1] [2] [3] [4] [5] [6] . Adverse events were mostly mild and intermittent and were either not treated or treated symptomatically. No patient discontinued the study because of side effects. Furthermore, the adverse event profile scores showed no significant differences and, in fact, showed a trend towards fewer side effects after the addition of lacosamide. Similarly, the neurotoxicity scale showed no statistically significant difference. This study is not without limitations including a small number of patients and not being a randomized, blinded, and placebo-controlled study. Additionally, although we has made every effort to reduce practice effects by using alternate versions of tests (in total, 4 of the 8 tests that included both verbal and visual memory), there are 4/8 tests that did not have an alternate version. Although we performed the retesting 6 months after the first test and sought reference from the Practitioner's guide to evaluating change with neuropsychological assessment instruments [23] assessing the impact of retesting of these specific measures, the inclusion of these 4 tests could be considered a limitation to the study's conclusions. In addition, it is a possibility that the reduction in seizures could have improved cognition and obscured possible effects of lacosamide.
An interesting future research direction might be to examine means and standard deviations of neurocognitive measures collected in the current study to the same tests used in previous studies of other AEDs as well as healthy controls. Moreover, randomized controlled studies might provide additional necessary evidence of the effects of lacosamide on cognition and mood.
In conclusion, this study's results suggest that lacosamide has low risks of adverse cognitive and mood effects and is effective as an adjunct therapy in refractory partial epilepsy.
